Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA

Free Radical Biology and Medicine

Volumn 27, Issue 3-4, 1999, Pages 428-437

  Martignoni, E ^a   Blandini, F ^b   Godi, L ^a   Desideri, S ^a   Pacchetti, C ^a   Mancini, F ^a   Nappi, G ^a,b  

^a Ctr Parkinson's Dis Movement D   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

3 O methyldopa; Dihydroxybenzoates; Free radicals; L DOPA; Parkinson's disease; Platelets; Superoxide dismutase

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; ANTIOXIDANT; DOPAMINE; DRUG METABOLITE; FREE RADICAL; HYDROXYL RADICAL; LEVODOPA; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE;

ANTIPARKINSON AGENTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; DOPAMINE; FEMALE; GENTISATES; HUMANS; HYDROXYBENZOIC ACIDS; HYDROXYL RADICAL; LEVODOPA; LINEAR MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; SODIUM SALICYLATE; SUPEROXIDE DISMUTASE; TYROSINE;

EID: 0032876022     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00075-1     Document Type: Article

References (58)

1. Jenner P. Oxidative damage in neurodegenerative diseases. Lancet. 344:1994;796-798.
2. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170.
3. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Javoy-Agid Y., Less A., Jenner P. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
4. Sanchez-Ramos J., Overvik E., Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2'deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration. 3:1994;197-204.
5. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunoistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA. 93:1996;2696-2713.
6. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive sopranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67:1986;269-274.
7. Sian J., Fexter D.T., Lees A.J., Daniel S., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355.
8. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130.
9. Saggu H., Cooksey J., Dexter D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53:1989;692-697.
10. Marttila R.J., Lorentz H., Rinne U.K. Oxygen toxicity protecting enzymes in Parkinson's disease increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus . J. Neurol. Sci. 86:1988;821-831.
11. Poirier J., Dea D., Baccichet A., Thiffault C. Superoxide dismutase expression in Parkinson's disease. Ann. N.Y. Acad. Sci. 738:1994;116-120.
12. Allen K.L., Almeida A., Bates T.E., Clark J.B. Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia. J. Neurochem. 64:1995;2222-2229.
13. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
14. Mizuno Y., Suzuki K., Ohta S. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J. Neurol. Sci. 96:1990;49-57.
15. Janetzky B., Hauck S., Youdim M.B.H., Riederer P., Jellinger K., Pantucek F., Zöchling R., Boissl K.W., Reichmann H. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 169:1994;126-128.
16. Checkoway H., Costa L.G., Woods J.S., Castoldi A.F., Lund B.O., Swanson P.D. Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease. J. Neural Transm. 4:1992;283-290.
17. Kushleika J., Checkoway H., Woods J.S., Moon J.D., Smith-Weller T., Franklin G.M., Swanson P.D. Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Ann. Neurol. 39:1996;378-381.
18. Bostantjopoulou S., Kyriazis G., Katsarou Z., Kiosseoglou G., Kazis A., Mentenopoulos G. Superoxide dismutase activity in early and advanced Parkinson's disease. Funct. Neurol. 12:1997;63-68.
19. Kilinc A., Yalcin A.S., Yalcin D., Taga Y., Emerk K. Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease. Neurosci. Lett. 87:1988;307-310.
20. Kalra J., Rajput A.H., Mantha S.V., Chaudhary A.K., Prasad K. Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol. Cell. Biochem. 112:1992;181-186.
21. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
22. Yoshino H., Nakagawa-Hattori Y., Kondo T., Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm. 4:1992;27-34.
23. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H.V. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32:1992;782-788.
24. Benecke R., Strümper P., Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain. 116:1993;1451-1463.
25. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37:1995;714-722.
26. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
27. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward c1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14:1978;644-653.
28. Spencer Smith T., Parker W.D., Bennet J.P. L-DOPA increases nigral production of hydroxyl radicals in vivo: potential L-DOPA toxicity? Neuroreport. 5:1994;1009-1011.
29. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., De Yebenes J.G. Toxic effects of L-DOPA on mesencephalic cell cultures protection with antioxidants . Brain Res. 682:1995;133-143.
30. Basma A.N., Morris E.J., Nicklas W.J., Geller H.M. L-DOPA cytotoxicity to PC12 cells in culture is via auto-oxidation. J. Neurochem. 64:1995;825-832.
31. Lai C.T., Yu P.H. Dopamine and L-Beta-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma. Biochem. Pharmacol. 53:1997;363-372.
32. Ziv I., Zilkha-Falb R., Offen D., Shirvan A., Barzilai A., Melamed E. Levodopa induced apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov. Disord. 1:1997;17-23.
33. Przedborski S., Jackson-Lewis V., Muthane U., Jiang H., Ferreira M., Naini A.B., Fahn S. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34:1993;715-723.
34. Pardo B., Mena M.A., Garcia de Yebenes J. L-DOPA inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J. Neurochem. 64:1995;576-582.
35. Nakao N., Nakai K., Itakura T. Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro. Brain Res. 777:1997;202-209.
36. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenic mechanism in Parkinson's disease. Neurosci. Lett. 170:1994;136-140.
37. Alexander T., Sortwell C.E., Sladek C.D., Roth R.H., Steece-Collier K. Comparison of neurotoxicity following repeated administration of L-DOPA, D-DOPA, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from fisher 344 and Sprague-Dawley donors. Cell Transplant. 6:1997;309-315.
38. Ahlskog J.E., Uitti R.J., Low P.A., Tyce G.M., O'Brien J.F., Nickander K.K. Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. Neurology. 46:1996;796-801.
39. Shults C.W., Nasirian F., Ward D.M., Nakano K., Pay M., Hill L.R., Haas R.H. Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Neurology. 45:1995;344-348.
40. Mytilineou C., Han S.K., Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J. Neurochem. 61:1993;1470-1478.
41. Han S.K., Mytilineou C., Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66:1996;501-510.
42. Miyoshi Y., Zhang Z., Ovadia A., Lapchak P.A., Collins F., Hilt D., Lebel C., Kryscio R., Gash D.M. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in Parkinsonian monkeys. Ann. Neurol. 42:1997;208-214.
43. Agid Y. Levodopa is toxicity a myth? Neurology. 50:1998;858-863.
44. Floyd R.A., Watson J.J., Wong P.K. Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol salicylate hydroxylation products. J. Biochem. Biophys. Methods. 10:1984;221-235.
45. Patthy M., Király I., Sziráki I. Separation of dihydroxybenzoates, indicators of in-vivo hydroxyl free radical formation, in the presence of transmitter amines and some metabolites in rodent brain, using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 664:1995;247-252.
46. + . Free Radic. Biol. Med. 13:1992;581-583.
47. Globus M.Y.T., Busto R., Lin B., Schnippering H., Ginsberg M.D. Detection of free radical activity during transient global ischemia and recirculation effects of intraischemic brain temperature modulation . J. Neurochem. 65:1995;1250-1256.
48. Giovanni A., Liang L.P., Hastings T.G., Zigmond M.J. Estimating hydroxyl radical content in rat brain using systemic and intraventicular salicylate impact of metamphetamine . J. Neurochem. 64:1995;1819-1825.
49. Obata T., Yamanaka Y. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation by monoamine oxidase inhibitor in the rat. Neurosci. Lett. 188:1995;13-16.
50. Leo R., Pratico D., Iuliano L., Pulcinelli F.M., Ghiselli A., Pignatelli P., Colavita A.R., Fitzgerald G.A., Violi F. Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation. 95:1997;885-891.
51. Blandini F., Martignoni E., Pacchetti C., Desideri S., Rivellini D., Nappi G. Simultaneous determination of L-DOPA and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B. 700:1997;278-282.
52. Blandini F., Nappi G., Greenamyre J.T. Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. Mov. Disord. 13:1998;11-15.
53. Lang A.E.T., Fahn S. Assessment of Parkinson's disease. Munsat T.L. Quantification of neurologic deficit. 1989;285-309 Buttersworth, Boston.
54. Pinamonti S., Chicca M.C., Muzzoli M., Papi A., Fabbri L.M., Ciaccia A. Oxygen radical scavengers inhibit clastogenic activity induced by sonication of human serum. Free Rad. Biol. Med. 16:1994;363-371.
55. Ingelman-Sundberg M., Kaur H., Terelius Y., Persson J., Halliwell B. Hydroxylation of salicylate by microsomal fractions and cytochrome P-450. Lack of production of 2,3-dihydroxybenzoate unless hydroxyl radical formation is permitted. Biochem. J. 276:1991;753-757.
56. Coudray C., Talla M., Martin S., Fatome M., Favier A. High-performance liquid chromatography - electrochemical determination of salicylate hydroxylation products as an in vivo marker of oxidative stress. Anal. Biochem. 227:1995;101-111.
57. Ghiselli A., Laurenti O., De Mattia G., Faiani G., Ferro-Luzzi A. Salicylate hydroxylation as an early marker of in vivo oxidative stress in diabetic patients. Free Radic. Biol. Med. 13:1992;621-626.
58. Olanow C.W., Jenner P., Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44:(Suppl. 1):1998;S167-S174.